These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 26195230

  • 21. Reproductive toxicity of denosumab in cynomolgus monkeys.
    Bussiere JL, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D, Farman C, Elliott G, Chellman G.
    Reprod Toxicol; 2013 Dec; 42():27-40. PubMed ID: 23886817
    [Abstract] [Full Text] [Related]

  • 22. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys.
    Prell RA, Dybdal N, Arima A, Chihaya Y, Nijem I, Halpern W.
    Toxicol Sci; 2018 Sep 01; 165(1):186-197. PubMed ID: 29893934
    [Abstract] [Full Text] [Related]

  • 23. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
    Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, Baker KP.
    Toxicol Sci; 2006 Jun 01; 91(2):586-99. PubMed ID: 16517838
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option.
    Stewart J.
    Reprod Toxicol; 2009 Sep 01; 28(2):220-5. PubMed ID: 19379807
    [Abstract] [Full Text] [Related]

  • 26. Intravitreal RTH258 (brolucizumab) demonstrates no effect on pregnancy, parturition, embryofetal or postnatal development in cynomolgus monkeys.
    Booler H, DeLise AM, Nimz E, Shefchek D, Luetjens CM.
    Reprod Toxicol; 2023 Oct 01; 121():108468. PubMed ID: 37666285
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Placental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis.
    Bowman CJ, Breslin WJ, Connor AV, Martin PL, Moffat GJ, Sivaraman L, Tornesi MB, Chivers S.
    Birth Defects Res B Dev Reprod Toxicol; 2013 Dec 01; 98(6):459-85. PubMed ID: 24391099
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies.
    Pentsuk N, van der Laan JW.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Aug 01; 86(4):328-44. PubMed ID: 19626656
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Multigenerational reproductive study of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study).
    National Toxicology Program.
    Natl Toxicol Program Tech Rep Ser; 2008 Mar 01; (539):1-266. PubMed ID: 18685713
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys.
    Moriyama T, Kakiuchi D, Grasso L, Hutto DL, Fernando D, Schweizer C.
    Reprod Toxicol; 2018 Aug 01; 79():89-95. PubMed ID: 29928988
    [Abstract] [Full Text] [Related]

  • 40. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor.
    Wehner NG, Shopp G, Oneda S, Clarke J.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr 01; 86(2):117-30. PubMed ID: 19278014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.